Cancer remains one of the leading causes of death worldwide, with treatment modalities often hindered by tumor heterogeneity, systemic toxicity, and drug resistance. Against this challenging backdrop, scientists have long sought therapeutic vectors capable of localizing treatment within tumors while minimizing harm to healthy tissues. The probiotic strain EcN, naturally residing in the human gut and known for its safety profile, emerged as an ideal chassis for such interventions. Exploiting its inherent tumor-colonizing capability, the researchers genetically engineered EcN to produce Romidepsin (also known as FK228), a potent histone deacetylase inhibitor with established anticancer properties.

Romidepsin functions by modulating epigenetic regulation, thereby inducing cancer cell apoptosis and cell cycle arrest. Traditionally administered systemically with significant side effects, its localized biosynthesis within the tumor microenvironment by engineered EcN offers a highly targeted alternative. By integrating the biosynthetic pathway of Romidepsin into the bacterial genome, the modified EcN strain can autonomously synthesize and secrete this therapeutic compound upon colonizing tumor sites.

The team’s meticulous in vitro assays demonstrated robust production of Romidepsin by the engineered EcN under different culture conditions simulating the tumor microenvironment. Crucially, these bacteria maintained their viability and sustained drug synthesis without compromising their probiotic characteristics. Proceeding to in vivo studies, the researchers employed a murine model bearing orthotopic breast tumors. Upon intravenous administration, the engineered EcN selectively homed to the tumor tissue, effectively bypassing healthy organs and minimizing systemic exposure.

Within the tumor niche, the colonizing bacteria proliferated and delivered continuous localized doses of Romidepsin, leading to significant tumor growth inhibition compared to control groups receiving non-engineered bacteria or systemic chemotherapy. Histopathological analyses revealed increased tumor cell apoptosis and reduced proliferation markers, corroborating the dual action of EcN’s colonization and Romidepsin’s pharmacological effects.

This study’s implications extend beyond efficacy; it addresses critical safety concerns associated with bacteria-mediated therapies. The authors emphasize the need to develop strategies for controlled elimination of the therapeutic bacteria post-treatment to prevent potential adverse outcomes such as unintended infections or systemic dissemination. Future research directives include refining bacterial strains for optimized drug yield, engineering kill-switch mechanisms, and conducting rigorous toxicological assessments to transition from animal models to human clinical trials.

The innovative design exploits the symbiotic relationship between host and microbiota, highlighting the untapped potential of the human microbiome as a therapeutic platform. The dual-action mechanism of EcN combined with Romidepsin not only augments the therapeutic index but also leverages the natural tumor tropism of bacteria, minimizing off-target drug effects. This synergy exemplifies a novel biological engineering feat offering personalized, precision oncology solutions.

Experts in the field have hailed this proof-of-concept work as a significant stride toward biodegradable, self-sustaining cancer treatments that circumvent the pitfalls of conventional chemotherapy. The use of a broadly recognized probiotic bacterium also enhances translational feasibility, reducing regulatory barriers frequently posed by pathogenic bacterial vectors.

Despite these promising findings, the authors note the complexity of human tumor microenvironments and inter-patient variability as considerable challenges. Comprehensive studies elucidating EcN’s long-term colonization dynamics, immune interactions, and integration with existing therapeutic regimens are essential steps before clinical translation.

This pioneering investigation sets a precedent for designing multifunctional bacterial platforms that can be tailored to produce diverse small-molecule drugs, enabling an unprecedented modular approach to cancer therapy. By harnessing synthetic biology, researchers can now envision intricate microbial therapeutics capable of sensing, responding to, and remodeling tumor ecosystems in real time.

In conclusion, this study from Shandong University charts a bold new course in the field of bacteria-assisted tumor therapy, paving the way for revolutionary treatments that combine biological engineering with precision medicine. The potential to bio-manufacture potent anticancer agents within tumors themselves could revolutionize cancer care, decreasing systemic toxicity and improving patient outcomes.

With continued advancements, engineered probiotic strains like EcN may soon emerge as frontline weapons against cancer, signaling a paradigm shift that integrates microbiology, genetic engineering, and oncology into a cohesive therapeutic strategy. As the field eagerly anticipates human trials, this research represents a beacon of hope for millions battling malignancies worldwide.

Subject of Research: Animals

Article Title: Engineered romidepsin biosynthetic pathways in Escherichia coli Nissle 1917 improve the efficacy of bacteria-mediated cancer therapy

News Publication Date: March 17, 2026

Web References:

• https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003657
• http://dx.doi.org/10.1371/journal.pbio.3003657

References:
Ma C, Li G, Sun T, Tang X, Qiu T, Song J, et al. (2026) Engineered romidepsin biosynthetic pathways in Escherichia coli Nissle 1917 improve the efficacy of bacteria-mediated cancer therapy. PLoS Biol 24(3): e3003657.

Keywords:
Synthetic biology, Escherichia coli Nissle 1917, Romidepsin, FK228, cancer therapy, tumor-targeted delivery, bacterial cancer therapy, epigenetic modulation, histone deacetylase inhibitor, probiotic engineering, bacterial colonization, breast cancer model

Colorectal cancer currently stands as the second leading cause of cancer-related deaths worldwide, with its aggressive nature and treatment resistance posing formidable challenges to oncologists and researchers alike. The urgency to discover new, more targeted cancer therapies has propelled scientists to explore unconventional methods, and this work represents a remarkable fusion of microbiology, chemistry, and oncology leading to promising new therapeutic avenues.

At the forefront of this innovation is Michael S. VanNieuwenhze, Ph.D., FRSC, a distinguished professor and chair of the Department of Biology at Baylor University. Alongside his team, including doctoral students Wyatt Paulishak and Jianan Lyu, and a collaborator from Texas Tech University Health Sciences Center, VanNieuwenhze has harnessed Listeria monocytogenes’ innate ability to invade human cells and engineered it to carry saporin, a robust ribosome-inactivating protein known for its cancer cell–killing properties.

The fundamental concept employed involves chemically attaching saporin molecules to the surface of Listeria bacteria. This bio-conjugation ensures that once Listeria invades the tumor cells—a process it naturally undertakes during infection—it delivers saporin directly into the cytosolic space. Saporin is only cytotoxic once internalized, and this method cleverly exploits Listeria’s intracellular trafficking pathways, overcoming the notorious challenge of delivering therapeutic payloads across cellular membranes and into the cytoplasm, thereby enhancing the efficacy of the delivered toxin.

Extensive in vitro and in vivo experiments have substantiated the superiority of this approach. Fluorescent imaging confirmed saporin’s successful attachment to Listeria and its subsequent delivery into target cancer cells. In preclinical mouse models representing sarcoma and microsatellite stable (MSS) colorectal cancer, the saporin-enhanced Listeria demonstrated significantly heightened cytotoxicity against tumor cells, translating to reduced tumor burden and promising therapeutic potential.

Beyond mere delivery, the modifications rendered to Listeria enhance safety and therapeutic effectiveness. Genetic attenuation has rendered the bacteria less virulent, ensuring that while they retain their cell-penetrating prowess, their pathogenic risks are minimized. This balance of safety and potency represents a crucial milestone in bacterial therapy development, navigating the complex regulatory and ethical challenges historically associated with using live microorganisms as drug carriers.

The versatility of this therapeutic vehicle lies in its ability to be fine-tuned for both endolysosomal targeting and direct cytoplasmic release of cytotoxic compounds, addressing multiple intracellular delivery challenges. Previous methodologies faced roadblocks due to lysosomal degradation or insufficient payload release. The dual-strategy approach employing antibody-drug conjugates (ADCs) and saporin-coupled bacteria elevates the potential for customizable and potent anti-cancer interventions adaptable to diverse tumor microenvironments.

Researchers also emphasize the immunological component inherent to Listeria monocytogenes. The bacteria’s presence stimulates innate and adaptive immune responses, which may synergize with the cytotoxic toxin delivery to enhance anti-tumor immunity. This dual functionality—as both a direct therapeutic delivery system and an immunostimulant—positions this bacterial platform as an especially attractive candidate for combinational therapies integrating immunotherapy and targeted cytotoxics.

Looking ahead, the Baylor team is focused on refining this technology to enable safer, scalable production and explore oral delivery modalities, which could revolutionize patient compliance and accessibility. Their vision encompasses genetically encoding Listeria to autonomously produce and release saporin within the tumor microenvironment, reducing the need for complex chemical conjugation and streamlining therapeutic protocols.

The interdisciplinary collaboration epitomized by this research signals a broader trend in precision oncology, where synthetic biology, chemistry, and molecular biology converge to engineer living therapeutics. Such innovations not only redefine conventional drug delivery paradigms but also expand the horizon for eradicating cancers once deemed refractory to standard treatments.

This pioneering work, published in Cell Chemical Biology on December 11, 2025, entitled “Bugs delivering drugs: Listeria monocytogenes-mediated cytotoxin delivery enhances anti-tumor activity in colorectal cancer,” underscores the transformative potential of leveraging microbial mechanisms for advanced cancer therapy. Importantly, all authors are listed as inventors on patent WO 2024/054673, which protects the intellectual property arising from this study.

Ultimately, this approach heralds a new class of living drug carriers, where the boundaries between biology and medicine seamlessly integrate, offering hope to millions battling colorectal and potentially other forms of cancer worldwide. The research community and patients alike will keenly watch the progression of this technology from experimental stages to clinical application, where its true impact on cancer survival and quality of life may be realized.

Subject of Research: Not applicable

Article Title: Bugs delivering drugs: Listeria monocytogenes-mediated cytotoxin delivery enhances anti-tumor activity in colorectal cancer

News Publication Date: 11-Dec-2025

Web References:

• Cell Chemical Biology Article
• National Cancer Institute Colorectal Cancer Statistics
• DOI: 10.1016/j.chembiol.2025.11.008

Image Credits: TTHSC/Baylor

Keywords: Listeria monocytogenes, colorectal cancer, drug delivery, saporin, bacterial therapy, cytotoxin, intracellular drug delivery, cancer immunotherapy, synthetic biology, oncology innovation, targeted therapy, bacterial vectors